Which has higher valuation & earnings, KRYS or QURE?

Krystal Biotech has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Krystal Biotech $389.13M 27.53 $204.83M $7.48 48.59 uniQure $16.10M 161.00 -$198.97M -$3.48 N/A

Is KRYS or QURE more profitable?

Krystal Biotech has a net margin of 53.92% compared to uniQure's net margin of -1,154.42%. Krystal Biotech's return on equity of 19.25% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets Krystal Biotech 53.92% 19.25% 17.62% uniQure -1,154.42% -145.81% -27.15%

Which has stronger valuation and earnings, QURE or CYTK?

uniQure has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio uniQure $16.10M 161.00 -$198.97M -$3.48 N/A Cytokinetics $88.04M 116.23 -$784.96M -$6.84 N/A

Is QURE or CYTK more profitable?

Cytokinetics has a net margin of -784.02% compared to uniQure's net margin of -1,154.42%. Cytokinetics' return on equity of 0.00% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,154.42% -145.81% -27.15% Cytokinetics -784.02% N/A -52.86%

Does the media refer more to QURE or CYTK?

In the previous week, Cytokinetics had 4 more articles in the media than uniQure. MarketBeat recorded 10 mentions for Cytokinetics and 6 mentions for uniQure. uniQure's average media sentiment score of 0.79 beat Cytokinetics' score of 0.43 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to QURE or KYMR?

In the previous week, Kymera Therapeutics had 3 more articles in the media than uniQure. MarketBeat recorded 9 mentions for Kymera Therapeutics and 6 mentions for uniQure. uniQure's average media sentiment score of 0.79 beat Kymera Therapeutics' score of 0.50 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kymera Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, QURE or NUVL?

uniQure has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio uniQure $16.10M 161.00 -$198.97M -$3.48 N/A Nuvalent N/A N/A -$425.38M -$6.06 N/A

Is QURE or NUVL more profitable?

Nuvalent has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Nuvalent's return on equity of -40.11% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,154.42% -145.81% -27.15% Nuvalent N/A -40.11% -35.43%

Does the media favor QURE or NUVL?

In the previous week, Nuvalent had 5 more articles in the media than uniQure. MarketBeat recorded 11 mentions for Nuvalent and 6 mentions for uniQure. uniQure's average media sentiment score of 0.79 beat Nuvalent's score of 0.52 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, QURE or IBRX?

uniQure has higher earnings, but lower revenue than ImmunityBio. uniQure is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio uniQure $16.10M 161.00 -$198.97M -$3.48 N/A ImmunityBio $113.29M 72.02 -$351.40M -$0.85 N/A

Is QURE or IBRX more profitable?

ImmunityBio has a net margin of -606.15% compared to uniQure's net margin of -1,154.42%. ImmunityBio's return on equity of 0.00% beat uniQure's return on equity. Company Net Margins Return on Equity Return on Assets uniQure -1,154.42% -145.81% -27.15% ImmunityBio -606.15% N/A -59.53%

Does the media refer more to QURE or IBRX?

In the previous week, ImmunityBio had 3 more articles in the media than uniQure. MarketBeat recorded 9 mentions for ImmunityBio and 6 mentions for uniQure. uniQure's average media sentiment score of 0.79 beat ImmunityBio's score of 0.32 indicating that uniQure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment uniQure 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

uniQure (QURE) Competitors

$41.10 -1.53 (-3.59%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$41.97 +0.87 (+2.11%)

As of 07:51 AM Eastern

Compare

QURE vs. KRYS, CYTK, KYMR, NUVL, and IBRX

Should you buy uniQure stock or one of its competitors? MarketBeat compares uniQure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with uniQure include Krystal Biotech (KRYS), Cytokinetics (CYTK), Kymera Therapeutics (KYMR), Nuvalent (NUVL), and ImmunityBio (IBRX). These companies are all part of the "pharmaceutical products" industry.

How does uniQure compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and uniQure (NASDAQ:QURE) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Krystal Biotech currently has a consensus price target of $352.00, indicating a potential downside of 3.15%. uniQure has a consensus price target of $64.17, indicating a potential upside of 56.12%. Given uniQure's higher possible upside, analysts clearly believe uniQure is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65

In the previous week, uniQure had 5 more articles in the media than Krystal Biotech. MarketBeat recorded 6 mentions for uniQure and 1 mentions for Krystal Biotech. Krystal Biotech's average media sentiment score of 1.87 beat uniQure's score of 0.79 indicating that Krystal Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Krystal Biotech	Very Positive
uniQure	Positive

Krystal Biotech has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$389.13M	27.53	$204.83M	$7.48	48.59
uniQure	$16.10M	161.00	-$198.97M	-$3.48	N/A

Krystal Biotech has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, uniQure has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Krystal Biotech has a net margin of 53.92% compared to uniQure's net margin of -1,154.42%. Krystal Biotech's return on equity of 19.25% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
uniQure	-1,154.42%	-145.81%	-27.15%

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Krystal Biotech beats uniQure on 11 of the 16 factors compared between the two stocks.

How does uniQure compare to Cytokinetics?

uniQure (NASDAQ:QURE) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, media sentiment, dividends and valuation.

Cytokinetics has a net margin of -784.02% compared to uniQure's net margin of -1,154.42%. Cytokinetics' return on equity of 0.00% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Cytokinetics	-784.02%	N/A	-52.86%

In the previous week, Cytokinetics had 4 more articles in the media than uniQure. MarketBeat recorded 10 mentions for Cytokinetics and 6 mentions for uniQure. uniQure's average media sentiment score of 0.79 beat Cytokinetics' score of 0.43 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

78.8% of uniQure shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 2.6% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

uniQure has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	161.00	-$198.97M	-$3.48	N/A
Cytokinetics	$88.04M	116.23	-$784.96M	-$6.84	N/A

uniQure currently has a consensus target price of $64.17, indicating a potential upside of 56.12%. Cytokinetics has a consensus target price of $99.90, indicating a potential upside of 21.47%. Given uniQure's higher probable upside, equities analysts plainly believe uniQure is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91

uniQure has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Summary

uniQure beats Cytokinetics on 10 of the 17 factors compared between the two stocks.

How does uniQure compare to Kymera Therapeutics?

uniQure (NASDAQ:QURE) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

uniQure presently has a consensus price target of $64.17, indicating a potential upside of 56.12%. Kymera Therapeutics has a consensus price target of $121.73, indicating a potential upside of 10.26%. Given uniQure's higher probable upside, equities research analysts clearly believe uniQure is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Kymera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	20 Buy rating(s)	1 Strong Buy rating(s)	2.91

Kymera Therapeutics has a net margin of -611.94% compared to uniQure's net margin of -1,154.42%. Kymera Therapeutics' return on equity of -24.71% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

In the previous week, Kymera Therapeutics had 3 more articles in the media than uniQure. MarketBeat recorded 9 mentions for Kymera Therapeutics and 6 mentions for uniQure. uniQure's average media sentiment score of 0.79 beat Kymera Therapeutics' score of 0.50 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kymera Therapeutics	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of uniQure shares are held by institutional investors. 4.7% of uniQure shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

uniQure has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	161.00	-$198.97M	-$3.48	N/A
Kymera Therapeutics	$39.21M	231.61	-$311.35M	-$3.57	N/A

uniQure has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.95, meaning that its stock price is 95% more volatile than the broader market.

Summary

Kymera Therapeutics beats uniQure on 11 of the 17 factors compared between the two stocks.

How does uniQure compare to Nuvalent?

uniQure (NASDAQ:QURE) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, media sentiment, dividends, earnings and valuation.

uniQure currently has a consensus target price of $64.17, suggesting a potential upside of 56.12%. Nuvalent has a consensus target price of $127.73, suggesting a potential upside of 3.06%. Given uniQure's stronger consensus rating and higher probable upside, research analysts plainly believe uniQure is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Nuvalent has a net margin of 0.00% compared to uniQure's net margin of -1,154.42%. Nuvalent's return on equity of -40.11% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
Nuvalent	N/A	-40.11%	-35.43%

In the previous week, Nuvalent had 5 more articles in the media than uniQure. MarketBeat recorded 11 mentions for Nuvalent and 6 mentions for uniQure. uniQure's average media sentiment score of 0.79 beat Nuvalent's score of 0.52 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

uniQure has higher revenue and earnings than Nuvalent. Nuvalent is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	161.00	-$198.97M	-$3.48	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

78.8% of uniQure shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 4.7% of uniQure shares are held by company insiders. Comparatively, 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

uniQure has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Nuvalent has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

Summary

uniQure beats Nuvalent on 9 of the 15 factors compared between the two stocks.

How does uniQure compare to ImmunityBio?

uniQure (NASDAQ:QURE) and ImmunityBio (NASDAQ:IBRX) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

78.8% of uniQure shares are held by institutional investors. Comparatively, 8.6% of ImmunityBio shares are held by institutional investors. 4.7% of uniQure shares are held by insiders. Comparatively, 66.1% of ImmunityBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

uniQure presently has a consensus price target of $64.17, suggesting a potential upside of 56.12%. ImmunityBio has a consensus price target of $14.20, suggesting a potential upside of 82.28%. Given ImmunityBio's stronger consensus rating and higher possible upside, analysts clearly believe ImmunityBio is more favorable than uniQure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.65
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, ImmunityBio had 3 more articles in the media than uniQure. MarketBeat recorded 9 mentions for ImmunityBio and 6 mentions for uniQure. uniQure's average media sentiment score of 0.79 beat ImmunityBio's score of 0.32 indicating that uniQure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ImmunityBio	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImmunityBio has a net margin of -606.15% compared to uniQure's net margin of -1,154.42%. ImmunityBio's return on equity of 0.00% beat uniQure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,154.42%	-145.81%	-27.15%
ImmunityBio	-606.15%	N/A	-59.53%

uniQure has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.01, suggesting that its stock price is 99% less volatile than the broader market.

uniQure has higher earnings, but lower revenue than ImmunityBio. uniQure is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10M	161.00	-$198.97M	-$3.48	N/A
ImmunityBio	$113.29M	72.02	-$351.40M	-$0.85	N/A

Summary

ImmunityBio beats uniQure on 9 of the 16 factors compared between the two stocks.

Get uniQure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QURE vs. The Competition

Export

Metric	uniQure	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.69B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-11.81	20.85	27.12	24.26
Price / Sales	161.00	314.01	587.25	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	12.88	8.49	10.89	6.29
Net Income	-$198.97M	$23.83M	$3.58B	$330.66M
7 Day Performance	-0.75%	-3.56%	-2.11%	-1.35%
1 Month Performance	49.08%	6.31%	3.28%	-0.64%
1 Year Performance	182.47%	48.30%	26.33%	19.08%

uniQure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QURE uniQure	3.7599 of 5 stars	$41.10 -3.6%	$64.17 +56.1%	+185.4%	$2.69B	$16.10M	N/A	500
KRYS Krystal Biotech	2.6248 of 5 stars	$365.81 -1.5%	$340.56 -6.9%	+145.3%	$10.94B	$389.13M	48.91	210	Positive News Analyst Forecast
CYTK Cytokinetics	2.4862 of 5 stars	$84.87 -1.4%	$99.90 +17.7%	+122.2%	$10.71B	$88.04M	N/A	250
KYMR Kymera Therapeutics	1.8936 of 5 stars	$119.35 +0.3%	$121.41 +1.7%	+148.2%	$9.79B	$39.21M	N/A	170	Analyst Downgrade Gap Down
NUVL Nuvalent	2.2876 of 5 stars	$123.90 +0.1%	$127.73 +3.1%	+53.1%	$9.78B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QURE) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

uniQure (QURE) Competitors

QURE vs. KRYS, CYTK, KYMR, NUVL, and IBRX

How does uniQure compare to Krystal Biotech?

Summary

How does uniQure compare to Cytokinetics?

Summary

How does uniQure compare to Kymera Therapeutics?

Summary

How does uniQure compare to Nuvalent?

Summary

How does uniQure compare to ImmunityBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

uniQure (QURE) Competitors

QURE vs. KRYS, CYTK, KYMR, NUVL, and IBRX

How does uniQure compare to Krystal Biotech?

Do analysts prefer KRYS or QURE?

Does the media favor KRYS or QURE?

Which has higher valuation & earnings, KRYS or QURE?

Which has more risk & volatility, KRYS or QURE?

Is KRYS or QURE more profitable?

Do institutionals & insiders believe in KRYS or QURE?

Summary

How does uniQure compare to Cytokinetics?

Is QURE or CYTK more profitable?

Does the media refer more to QURE or CYTK?

Do insiders and institutionals believe in QURE or CYTK?

Which has stronger valuation and earnings, QURE or CYTK?

Do analysts rate QURE or CYTK?

Which has more volatility and risk, QURE or CYTK?

Summary

How does uniQure compare to Kymera Therapeutics?

Do analysts rate QURE or KYMR?

Is QURE or KYMR more profitable?

Does the media refer more to QURE or KYMR?

Do institutionals & insiders believe in QURE or KYMR?

Which has better earnings & valuation, QURE or KYMR?

Which has more volatility & risk, QURE or KYMR?

Summary

How does uniQure compare to Nuvalent?

Do analysts recommend QURE or NUVL?

Is QURE or NUVL more profitable?

Does the media favor QURE or NUVL?

Which has better earnings and valuation, QURE or NUVL?

Do institutionals & insiders have more ownership in QURE or NUVL?

Which has more volatility and risk, QURE or NUVL?

Summary

How does uniQure compare to ImmunityBio?

Do insiders & institutionals have more ownership in QURE or IBRX?

Do analysts recommend QURE or IBRX?

Does the media refer more to QURE or IBRX?

Is QURE or IBRX more profitable?

Which has more risk & volatility, QURE or IBRX?

Which has higher earnings & valuation, QURE or IBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QURE vs. The Competition

uniQure Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools